Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 5/20 | 0.70 |
| ▸ | DRD3 | P35462 | 5/20 | 0.70 |
| ▸ | DRD1 | P21728 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 6/20 | 0.67 |
| ▸ | DRD4 | P21917 | 3/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.65 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | HRH1 | P35367 | 3/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Primaperone SCHEMBL364809 | 0.98 | TSHR (0.76) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL4496558 | 0.98 | TSHR (0.76) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL11755100 | 0.90 | ALDH1A1 (0.71) | TSHRHTR1AADRA1AKCNH2HRH3 | |
| Primaperone SCHEMBL30110541 | 0.90 | TSHR (0.68) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL7350313 | 0.89 | ALDH1A1 (0.68) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL11790502 | 0.87 | HTR1A (0.69) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL7375822 | 0.87 | HRH3 (0.58) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL7378554 | 0.87 | HRH3 (0.58) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL28432024 | 0.86 | TSHR (0.72) | TSHRHTR1ADRD3DRD1ADRA2A | |
| SCHEMBL16986166 | 0.86 | TSHR (0.97) | TSHRHTR1ADRD3DRD1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4772616-A | DOMPERIDONE | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1988-09-20 | — | — | US | disclosed |
| US-4284638-A | Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine | CIBA-GEIGY CORPORATION (US) | 1981-08-18 | — | — | US | disclosed |
| US-3936468-A | PSYCHOTROPIC | SUMITOMO CHEMICAL COMPANY, LTD. (JA) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | TSHR 2997/4885HTR1A 3926/4885DRD3 4661/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | TSHR 4456/4885HTR1A 660/4885DRD3 3204/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | TSHR 105/4885HTR1A 228/4885DRD3 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.